Circulating tumor cells in locally advanced pancreatic adenocarcinoma: The ancillary CirCe 07 study to the LAP 07 trial

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2057-2061

  Bidard, F C ^a,b   Huguet, F ^c   Louvet, C ^d   Mineur, L ^e   Bouche O ^f   Chibaudel, B ^g   Artru, P ^h   Desseigne, F ⁱ   Bachet, J B ^j   Mathiot, C ^a   Pierga, J Y ^a,b   Hammel, P ^k  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL TENON   (France)

^d INSTITUT MUTUALISTE MONTSOURIS   (France)

^e INSTITUT SAINTE CATHERINE   (France)

^f SERVICE DE DERMATOLOGIE   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h Hopital Prive Jean Mermoz   (France)

ⁱ CENTRE LÉON BÉRARD   (France)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k BEAUJON HOSPITAL   (France)

more..

Author keywords

Chemoradiotherapy; CirCe 07; Circulating tumor cells; Gemcitabine; LAP 07; Locally advanced pancreatic cancer

Indexed keywords

ERLOTINIB; GEMCITABINE;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; MULTICENTER STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

CHEMORADIOTHERAPY; CIRCE 07; CIRCULATING TUMOR CELLS; GEMCITABINE; LAP 07; LOCALLY ADVANCED PANCREATIC CANCER;

ADENOCARCINOMA; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; COHORT STUDIES; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84881221655     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt176     Document Type: Article

References (24)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Hochster HS, Haller DG, de Gramont A et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006; 107: 676-685.
3. Iacobuzio-Donahue CA, Fu B, Yachida S et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806-1813.
4. Huguet F, Girard N, Guerche CS et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009; 27: 2269-2277.
5. Huguet F, Andre T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331.
6. Bidard FC, Pierga JY, Soria JC, Thiery JP. Translating metastasis-related biomarkers to the clinic-progress and pitfalls. Nat Rev Clin Oncol 2013; 10: 169-179.
7. Rehders A, Stoecklein NH, Guray A et al. Vascular invasion in pancreatic cancer: Tumor biology or tumor topography? Surgery 2012; 152(3 Suppl 1): S143-S151.
8. Bidard FC, Ferrand FR, Huguet F et al. Disseminated and circulating tumor cells in gastrointestinal oncology. Crit Rev Oncol Hematol 2012; 82: 103-115.
9. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904.
10. Krishnan S, Rana V, Janjan NA et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 2006; 107: 2589-2596.
11. Dalal S, Hui D, Bidaut L et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage 2012; 44: 181-191.
12. Bjerregaard JK, Mortensen MB, Jensen HA et al. Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012; 83: 909-915.
13. Bauer TM, El-Rayes BF, Li X et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer 2013; 119: 285-292.
14. Kurihara T, Itoi T, Sofuni A et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg 2008; 15: 189-195.
15. Ko AH, Scott J, Tempero MA, Park JW. Detection and significance of circulating tumor cells (CTC) in patients with metastatic pancreatic cancer (PC) receiving systemic therapy. ASCO Meeting Abstracts 2007; 25: 4596.
16. Negin BP, Meropol NJ, Alpaugh RK et al. Characterization and prognostic significance of circulating tumor cells in the peripheral blood of patients with metastatic pancreatic cancer. ASCO Meeting Abstracts 2010; 28: 4127.
17. Z'Graggen K, Centeno BA, Fernandez-del Castillo C et al. Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. Surgery 2001; 129: 537-546.
18. Soeth E, Grigoleit U, Moellmann B et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol 2005; 131: 669-676.
19. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
20. Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012; 23: 618-624.
21. Bidard FC, Mathiot C, Delaloge S et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 21: 729-733.
22. Giordano A, Egleston BL, Hajage D et al. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res 2013; 19: 1596-1602.
23. Yu M, Ting DT, Stott SL et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012; 487: 510-513.
24. Muller V, Riethdorf S, Rack B et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012; 14: R118.